Market News AIOpen the app

BLSM stock news · BlossomHill Therapeutics, Inc.

Stories about BlossomHill Therapeutics, Inc. (BLSM) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for BLSM

Follow BlossomHill Therapeutics, Inc. (BLSM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BLSM
Free on the App Store and Google Play, or on the web.
  1. Nov 12, 2026, 4:47 PM ET · Results

    BlossomHill Therapeutics, Inc.: Results of Operations and Financial Condition (BLSM)

    Good for BLSM

    BlossomHill said the FDA agreed on a 50 mg twice-daily dose and outlined a pivotal trial for 2027. Early results support progress, despite a wider $24.0 million quarterly loss.

  2. Sep 18, 2026, 7:23 AM ET · Market

    BlossomHill Therapeutics, Inc. shares how they are doing financially and with their business.

    Neutral

    BlossomHill filed an 8-K linking a Sept 18 press release. The filing here provides no figures, so it does not change my view.

  3. Sep 18, 2026, 7:17 AM ET · Results

    BlossomHill Therapeutics will share its second-quarter earnings on September 18, 2026.

    Neutral

    BlossomHill will report Q2 results tomorrow; this schedule-only notice provides no results, so it does not change how we read the company.

  4. Sep 15, 2026, 7:35 AM ET · Market

    BlossomHill Therapeutics, Inc. shares important information in a filing with the SEC.

    Neutral

    BlossomHill filed a Regulation FD disclosure and press release; the filing included no business data, so we see no change for the company.